Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | RARA | P10276 | 1/20 | 0.41 |
| ▸ | RARB | P10826 | 1/20 | 0.41 |
| ▸ | RARG | P13631 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27745237 | 0.85 | TDP1 (0.53) | HPGDKMT2AALDH1A1GAAMAPT | |
| SCHEMBL5269393 | 0.85 | TSHR (0.47) | KMT2AALDH1A1MAPTTSHRNPC1 | |
| SCHEMBL5269260 | 0.83 | ALDH1A1 (0.40) | HPGDKMT2AALDH1A1GAAMAPT | |
| SCHEMBL1199301 | 0.80 | CYP2C19 (0.45) | HPGDKMT2AALDH1A1GAAMAPT | |
| SCHEMBL5267233 | 0.80 | MAPT (0.42) | HPGDKMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL5267243 | 0.79 | ALKBH2 (0.53) | MAPTSMN1; SMN2TSHRHTTNPC1 | |
| SCHEMBL31409578 | 0.79 | CYP2C19 (0.43) | HPGDALDH1A1GAASMN1; SMN2TSHR | |
| SCHEMBL31409579 | 0.77 | CYP2C19 (0.42) | HPGDALDH1A1GAAMAPTSMN1; SMN2 | |
| SCHEMBL31352171 | 0.77 | CYP2C19 (0.42) | HPGDKMT2AALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL2411096 | 0.76 | HPGDS (0.62) | HPGDKMT2AALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170002011-A1 | BENZENE SULFONAMIDES AS CCR9 INHIBITORS | NORGINE B.V. (NL) | 2017-01-05 | — | — | US | disclosed |
| US-20170002011-A1 | BENZENE SULFONAMIDES AS CCR9 INHIBITORS | NORGINE B.V. (NL) | 2017-01-05 | — | — | US | disclosed |
| EP-3087074-A1 | BENZENE SULFONAMIDES AS CCR9 INHIBITORS | Norgine BV (NL) | 2016-11-02 | — | — | EP | disclosed |
| EP-2099452-B1 | TRICARBONYL COMPLEXES WITH TRIDENTATE CHELATORS FOR MYOCARDIUM IMAGING | MALLINCKRODT LLC (US) | 2015-07-22 | — | — | EP | disclosed |
| WO-2015097122-A1 | BENZENE SULFONAMIDES AS CCR9 INHIBITORS | NORGINE B.V. (NL) | 2015-07-02 | — | — | WO | disclosed |
| US-9023315-B2 | Tricarbonyl complexes with tridentate chelators for myocardium imaging | MALLINCKRODT LLC (US) | 2015-05-05 | — | — | US | disclosed |
| US-8940273-B2 | Tricarbonyl complexes with tridentate chelators for myocardium imaging | MALLINCKRODT LLC (US) | 2015-01-27 | — | — | US | disclosed |
| US-20130129620-A1 | Tricarbonyl Complexes with Tridentate Chelators for Myocardium Imaging | MALLINCKRODT LLC (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131327-A1 | Tricarbonyl Complexes with Tridentate Chelators for Myocardium Imaging | MALLINCKRODT LLC (US) | 2013-05-23 | — | — | US | disclosed |
| US-8372379-B2 | Technetium-99m (I) tricarbonyl complexes with tridentate chelators for myocardium imaging | MALLINCKRODT LLC (US) | 2013-02-12 | — | — | US | disclosed |
| US-6468995-B1 | ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-10-22 | — | — | US | disclosed |
| EP-0667868-B1 | CEPHEM COMPOUNDS | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-05-15 | — | — | EP | disclosed |
| EP-0783495-B1 | QUINOXALINE DERIVATIVES USEFUL IN THERAPY | PFIZER LTD (GB) | 2002-02-27 | — | — | EP | disclosed |
| US-5852016-A | Quinoxaline derivatives useful in therapy | PFIZER INC. (US) | 1998-12-22 | — | — | US | disclosed |
| EP-0783495-A1 | QUINOXALINE DERIVATIVES USEFUL IN THERAPY | Pfizer Limited (GB) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996009295-A1 | QUINOXALINE DERIVATIVES USEFUL IN THERAPY | PFIZER LIMITED (GB) | 1996-03-28 | — | — | WO | disclosed |
| WO-1995007283-A1 | NEW CEPHEM COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-16 | — | — | WO | disclosed |
| EP-0091130-B1 | CEPHALOSPORIN DERIVATIVES, PROCESS FOR PREPARING AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS | DAIICHI SEIYAKU CO., LTD. (JP) | 1987-04-08 | — | — | EP | disclosed |
| US-4603198-A | Cephalosporin derivatives | DAIICHI SEIYAKU CO., LTD. (JP) | 1986-07-29 | — | — | US | disclosed |
| EP-0091130-A2 | Cephalosporin derivatives, process for preparing and pharmaceutical compositions containing said compounds | DAIICHI SEIYAKU CO., LTD. (JP) | 1983-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131327-A1 | Tricarbonyl Complexes with Tridentate Chelators for Myocardium Imaging | TNNT2, TNNI3, FABP3 | HPGD 3359/4885KMT2A 2725/4885ALDH1A1 3518/4885 |
| US-20170002011-A1 | BENZENE SULFONAMIDES AS CCR9 INHIBITORS | CCR9, CCR1, CCR4 | HPGD 2107/4885KMT2A 2961/4885ALDH1A1 2381/4885 |
| US-20130129620-A1 | Tricarbonyl Complexes with Tridentate Chelators for Myocardium Imaging | TNNT2, TNNI3, FABP3 | HPGD 3359/4885KMT2A 2725/4885ALDH1A1 3518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.